Cargando…
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
OBJECTIVE: The aim of the present subgroup analysis of the FRESCO trial is to determine the efficacy and hepatotoxicity of fruquintinib in Chinese patients with metastatic CRC with liver metastasis (CRLM) who were receiving third-line or posterior-line therapy. METHODS: Overall survival (OS) and pro...
Autores principales: | Qin, Shukui, Xu, Rui-Hua, Shen, Lin, Xu, Jianming, Bai, Yuxian, Yang, Lei, Deng, Yanhong, Chen, Zhen-dong, Zhong, Haijun, Pan, Hongming, Guo, Weijian, Shu, Yongqian, Yuan, Ying, Zhou, Jianfeng, Xu, Nong, Liu, Tianshu, Ma, Dong, Wu, Changping, Cheng, Ying, Chen, Donghui, Li, Wei, Sun, Sanyuan, Yu, Zhuang, Cao, Peiguo, Chen, Haihui, Wang, Jiejun, Wang, Shubin, Wang, Hongbing, Wang, Ning, Zhang, Bin, Zhang, Qiang, Su, Weiguo, Guo, Xiaojun, Li, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364970/ https://www.ncbi.nlm.nih.gov/pubmed/34408440 http://dx.doi.org/10.2147/OTT.S307273 |
Ejemplares similares
-
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
por: Xu, Rui-Hua, et al.
Publicado: (2017) -
Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022) -
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
por: Jin, Ying, et al.
Publicado: (2022) -
A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer
por: Zhang, Yang, et al.
Publicado: (2022) -
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
por: Liu, Xinyang, et al.
Publicado: (2018)